Fig. 2: Evaluating antitumor therapeutic ability of BC19 CAR T cells in vivo.

a Schematic diagram of evaluating in vivo anti-BCMA⁺ tumor activities of BC19 CAR T. 2 × 10⁶ U266 cells, endogenously expressing BCMA, were injected into NCG mice via the tail vein on day −7. Γ-secretase inhibitor LY3039478, orally administrated into the mice at 1 mg/kg three times per week, was used to maintain BCMA expression on the surface of U266 cells in mice. Mice were randomly divided into 4 groups and injected with a single dose of 2 × 10⁶ BCMA CAR T, CD19 CAR T, BC19 CAR T, or mock T cells via the tail vein on day 0. b In vivo tumor growth was evaluated by luciferase live imaging on days 0, 14, 21, 28, 35, and 42. c The bioluminescence value was monitored (Mock T and CD19 CAR T, n = 3; BCMA CAR T and BC19 CAR T, n = 4). Data are presented as mean ± SEM and analyzed by one-way analysis of variance (ANOVA) followed by Dunnett’s test. d Overall survival of the mice was graphically represented as Kaplan–Meier curves and analyzed by using the log-rank test. e Schematic diagram of evaluating in vivo anti-CD19⁺ tumor activities of BC19 CAR T. 1 × 10⁶ Nalm6 cells were injected into each NCG mouse on day −7. The mice were treated with 2 × 10⁶ BCMA CAR T, CD19 CAR T, BC19 CAR T, or mock T cells on day 0, respectively. In vivo tumor growth was evaluated (f, g), and mortality (h) of the mice was monitored (n = 4). Data are presented as mean ± SD, a two-tailed Student t-test was performed for two group comparisons. One-way ANOVA analysis of variance was used to determine the statistically significant difference for multiple group comparisons. Survival of mice was determined using Kaplan–Meier and compared using the log-rank test. Statistics: one-way ANOVA followed by Tukey’s multiple comparisons test (c, g), log-rank test (d, h). Source data are provided in the Source Data file.